No Prescription |
 |
 | ||
|
Abamune L Kivexa |
|
| ||
No Prescription » Prescription Drugs 1 » Abamune L Kivexa Abamune L contain two active ingredients abacavir and lamivudine (also known as 3TC). These are both medicines called nucleoside reverse transcriptase inhibitors (NRTIs). They are used in the treatment of HIV (human immunodeficiency virus) infection. Buy Abamune L Kivexa and other Prescription Drugs 1 products online at Medstore. Buy Online at Medstore - Click Here!
About Abamune L Kivexa: Product Type: Prescription Drugs 1 Abamune L ( Kivexa Generic Abacavir/Lamivudine) Abamune L (Kivexa Generic Abacavir/Lamivudine) Kivexa Generic Abacavir/Lamivudine 600/300mg 60(2 x 30 Tablets) 600/300mg 90(3 x 30 Tablets) 600/300mg 30 Tablets Kivexa Generic Abacavir/Lamivudine Abamune L
View more Prescription Drugs 1 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
